(Q46754187)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

title

EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Michael Lassmann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Glenn D Flux

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Francesco Giammarile

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Boudewijn Brans

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

EANM

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

number of pages

9

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

1039-1047

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18274745%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-008-0715-3

2 January 2020

exact match

0 references

cites work

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

1 reference

12 December 2020

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma

1 reference

12 December 2020

Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine

1 reference

12 December 2020

Optimization of equipment and methodology for whole body activity retention measurements in children undergoing targeted radionuclide therapy.

1 reference

12 December 2020

Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG.

1 reference

12 December 2020

Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study

1 reference

12 December 2020

Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection

1 reference

12 December 2020

Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation

1 reference

12 December 2020

A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG)

1 reference

12 December 2020

Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours

1 reference

12 December 2020

Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry

1 reference

12 December 2020

Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives

1 reference

12 December 2020

Radiation dose to patients from radiopharmaceuticals. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection

1 reference

12 December 2020

Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma

1 reference

12 December 2020

Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy.

1 reference

12 December 2020

Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.

1 reference

12 December 2020

Dosimetry for Fractionated 131I-mIBG Therapies in Patients with Primary Resistant High-Risk Neuroblastoma: Preliminary Results

1 reference

12 December 2020

Guidelines for guideline development. Society of Nuclear Medicine

1 reference

12 December 2020

Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.

1 reference

12 December 2020

Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine

1 reference

12 December 2020